Krystal Biotech, Inc. KRYS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s total current liabilities?
- Krystal Biotech, Inc. (KRYS) reported total current liabilities of $107.8M in Q1 2026.
- How has Krystal Biotech, Inc.'s total current liabilities changed year-over-year?
- Krystal Biotech, Inc.'s total current liabilities increased by 35.6% year-over-year, from $79.49M to $107.8M.
- What is the long-term trend for Krystal Biotech, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total current liabilities has grown at a 46.1% compound annual growth rate (CAGR), from $15.45M to $102.94M.
- What does total current liabilities mean?
- The total amount of debt and other obligations the company must pay within one year.
- How do you interpret total current liabilities?
- A rising trend relative to current assets may signal liquidity pressure, while a stable or decreasing trend suggests healthy short-term financial management.
- How does total current liabilities compare across companies?
- Standard metric; peers with similar business models should have comparable current liability structures relative to their revenue.